How Much Does Zepbound Cost in South Carolina in 2026?

Zepbound Retail Price in South Carolina

The standard cash price for Zepbound at South Carolina retail pharmacies sits at $1,059 per month in 2026, matching the manufacturer list price set by Eli Lilly. This figure applies to all four maintenance doses (5 mg, 10 mg, and 15 mg single-dose pens, each dispensed as a four-pen monthly carton) as well as the 2.5 mg starter dose. Pharmacy-to-pharmacy variation in South Carolina is minimal because Lilly distributes through contracted wholesalers at a uniform wholesale acquisition cost.

Patients paying entirely out of pocket can expect to spend between $12,708 and $12,708 annually at list price. That number has not changed since the drug's November 2023 FDA approval for chronic weight management. Some independent pharmacies and regional chains in Columbia, Charleston, and Greenville may offer modest discounts through manufacturer rebate pass-throughs, but these reductions rarely bring the monthly cost below $1,000 without additional savings programs.

Price comparison tools such as GoodRx and RxSaver occasionally list Zepbound below $1,059 at specific SC locations, though availability fluctuates by zip code. The gap between sticker price and what patients actually pay depends almost entirely on insurance status and savings card eligibility.

Insurance Coverage for Zepbound in South Carolina

Coverage varies widely by plan type, carrier, and employer. BlueCross BlueShield of South Carolina, the state's largest commercial insurer, has added tirzepatide to certain formularies for obesity treatment, but tier placement and prior authorization requirements differ by plan year. Patients with employer-sponsored coverage through national carriers like UnitedHealthcare, Aetna, or Cigna should request a formulary exception or prior authorization if Zepbound is not listed.

Prior authorization criteria typically require documented BMI ≥30 (or ≥27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), a history of failed lifestyle interventions, and sometimes trial-and-failure of an older anti-obesity medication. These requirements mirror the FDA label population studied in SURMOUNT-1, where tirzepatide 15 mg produced a 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo (N=2,539) [1].

A practical step: call the number on the back of your insurance card and ask for the pharmacy benefit department. Request a "coverage determination" for Zepbound using NDC 00002-1752-80 (the 5 mg carton). If the plan denies coverage, ask your prescriber to submit a peer-to-peer review or a step-therapy exception.

South Carolina Medicaid and Zepbound

South Carolina Medicaid does not cover Zepbound for chronic weight management as of May 2026. This exclusion follows a pattern seen across most state Medicaid programs, where anti-obesity medications remain classified as "drugs used for anorexia, weight loss, or weight gain" under Section 1927(d)(2) of the Social Security Act, which allows states to exclude them from coverage [2].

The practical impact is significant. South Carolina enrolled approximately 1.4 million people in Medicaid and CHIP as of early 2026, and the state's adult obesity rate exceeds 36% according to the CDC's Behavioral Risk Factor Surveillance System [3]. Medicaid beneficiaries who need pharmacotherapy for obesity currently have no covered GLP-1-based option in the state.

Federal legislation introduced in 2024 (the Treat and Reduce Obesity Act) would have required Medicaid coverage of FDA-approved anti-obesity medications, but the bill did not advance to a floor vote. Until federal law changes or South Carolina's Department of Health and Human Services issues a State Plan Amendment, Medicaid enrollees must pursue alternatives: compounded tirzepatide, manufacturer patient assistance programs, or clinical trial enrollment.

Compounded Tirzepatide in South Carolina

Licensed 503A compounding pharmacies in South Carolina can legally prepare tirzepatide formulations. These pharmacies operate under state Board of Pharmacy oversight and must compound from bulk drug substance in response to individual patient prescriptions. The average price for compounded tirzepatide in South Carolina is approximately $249 per month, a 76% reduction from the brand-name list price.

A few critical distinctions apply. Compounded tirzepatide is not FDA-approved. It has not undergone the manufacturing quality controls, bioequivalence testing, or stability studies required of Lilly's branded product. The FDA has issued guidance warning patients about potential risks with compounded versions of GLP-1 receptor agonists, including dosing inconsistencies and sterility concerns [4].

South Carolina patients considering compounded tirzepatide should verify three things before filling a prescription:

1. The pharmacy holds a valid South Carolina 503A compounding license (searchable via the SC Board of Pharmacy's online verification tool).
2. The pharmacy uses USP 797-compliant sterile compounding facilities.
3. The prescriber has confirmed the dose, concentration, and injection volume match the patient's titration schedule.

Dr. W. Timothy Garvey, professor of medicine at the University of Alabama at Birmingham and lead author of the AACE obesity treatment guidelines, has noted: "Compounded GLP-1 agonists fill a real access gap, but patients need to understand they are not getting the same product that was tested in clinical trials" [5].

How the Eli Lilly Zepbound Savings Card Works in SC

Eli Lilly's Zepbound Savings Card is the single largest cost reducer for commercially insured patients in South Carolina. Eligible patients pay as little as $25 per month for up to 12 months, with the card covering the remaining cost up to a maximum benefit. The card is available to patients with commercial insurance that covers Zepbound, even if the plan imposes a high copay or coinsurance.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance, not be enrolled in any federal or state-funded program (Medicare, Medicaid, Tricare, VA), and have a valid Zepbound prescription. Patients can enroll at Lilly's dedicated savings portal or through their prescriber's office.

For commercially insured patients whose plans do not cover Zepbound at all, Lilly offers a separate cash-pay savings program. Under this program, patients without coverage can obtain Zepbound for approximately $550 per month, cutting the list price nearly in half. This option became available in early 2025 and remains active in South Carolina.

One limitation worth noting: savings card benefits reset annually, and Lilly can modify or discontinue the program at any time. Patients should confirm current terms before each refill cycle.

Telehealth Access to Zepbound in South Carolina

South Carolina permits telehealth prescribing of Zepbound. State law (SC Code § 40-47-37) allows physicians and advanced practice providers to prescribe controlled and non-controlled medications via synchronous audio-video encounters without requiring an initial in-person visit. Tirzepatide is not a controlled substance, which simplifies the prescribing pathway.

Several national telehealth platforms now serve South Carolina residents for GLP-1 prescribing, including Ro, Hims, Found, and Calibrate. HealthRX also provides telehealth-based evaluation and prescribing for patients who qualify. The typical workflow involves a medical intake questionnaire, a video consultation with a licensed prescriber, lab work (often including HbA1c, metabolic panel, and lipid panel), and ongoing monthly check-ins for dose titration.

Telehealth visits for obesity pharmacotherapy in South Carolina typically cost between $99 and $199 for the initial consultation, with follow-up visits ranging from $49 to $99 per month depending on the platform. These fees are separate from the medication cost. Some platforms bundle medication and consultation into a single monthly fee, particularly when dispensing compounded tirzepatide.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option for adults with BMI ≥30, noting the "clinically meaningful weight reduction and cardiometabolic improvements observed across the SURMOUNT trial program" [6].

Clinical Efficacy: What the Trials Show

Understanding what Zepbound can do helps contextualize whether the cost is justified. In SURMOUNT-1 (N=2,539), participants randomized to tirzepatide 15 mg lost an average of 22.5% of body weight over 72 weeks, compared to 2.4% in the placebo group [1]. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose achieved 16.0%.

These results exceed those seen with semaglutide 2.4 mg (Wegovy) in the STEP-1 trial (N=1,961), which demonstrated 14.9% weight loss at 68 weeks versus 2.4% with placebo [7]. The difference matters clinically: tirzepatide's dual GIP/GLP-1 receptor agonism produces greater weight reduction than GLP-1-only agents across comparable trial populations.

SURMOUNT-2 (N=938) focused specifically on adults with type 2 diabetes and obesity. Participants on tirzepatide 15 mg lost 14.7% of body weight at 72 weeks, compared to 3.2% with placebo. HbA1c dropped by 2.1 percentage points in the 15 mg group [8]. For South Carolina patients with both obesity and type 2 diabetes, these data support tirzepatide as a treatment addressing both conditions simultaneously.

Side effects are dose-dependent and predominantly gastrointestinal. In SURMOUNT-1, nausea occurred in 24.6% of participants on the 5 mg dose, 33.3% on 10 mg, and 31.0% on 15 mg. Most nausea was mild to moderate and concentrated during the dose-escalation phase. Discontinuation due to adverse events occurred in 4.3% to 7.1% of tirzepatide-treated participants, compared to 2.6% with placebo [1].

Strategies to Lower Zepbound Cost in South Carolina

South Carolina patients have several concrete options for reducing out-of-pocket spending.

Use the Lilly savings card first. If you have commercial insurance that covers Zepbound (even with a high copay), apply for the savings card to bring your cost to $25 per month. This is the lowest available price for brand-name Zepbound.

Request a formulary exception. If your insurer does not list Zepbound, ask your prescriber to submit a prior authorization with supporting documentation: BMI, comorbidities, previous weight-loss attempts, and relevant trial data from SURMOUNT-1. Include a letter of medical necessity referencing the American Association of Clinical Endocrinology (AACE) obesity guidelines [5].

Consider the Lilly cash-pay program. Uninsured or underinsured patients can access Zepbound at approximately $550 per month through Lilly's direct program, a 48% savings versus list price.

Evaluate compounded tirzepatide. At roughly $249 per month through licensed South Carolina 503A pharmacies, compounded tirzepatide offers the lowest price point. Weigh this against the trade-offs discussed above regarding quality assurance and regulatory status.

Check employer wellness benefits. Some large South Carolina employers (BMW Manufacturing in Spartanburg, Michelin in Greenville, MUSC Health in Charleston) have added anti-obesity medication coverage to their self-funded health plans. Ask your HR benefits coordinator directly.

Explore patient assistance. Lilly's patient assistance program (Lilly Cares) provides free medication to qualifying low-income patients. Eligibility is income-based, typically at or below 400% of the federal poverty level.

Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has stated: "The cost of anti-obesity medications should be weighed against the cost of untreated obesity, which drives $173 billion in annual U.S. healthcare spending" [9].

Dose Titration and Monthly Cost Timeline

Zepbound follows a fixed titration schedule that affects early-month costs. The starting dose is 2.5 mg weekly for four weeks, then 5 mg weekly. From there, the prescriber may increase to 10 mg and then 15 mg at four-week intervals based on tolerability and response.

Each dose level costs the same at retail ($1,059 per month for brand-name). This means patients pay full price from month one, even during the 2.5 mg initiation phase when therapeutic effect is still building. The Lilly savings card and cash-pay program also apply uniformly across dose levels.

A complete 72-week treatment course at list price costs $16,944 (16 months × $1,059). With the savings card at $25 per month, that same course costs $400. With compounded tirzepatide at $249 per month, the total reaches $3,984. These numbers exclude prescriber visit fees, lab work, and any required monitoring.

According to a cost-effectiveness analysis published in JAMA Network Open, tirzepatide for obesity met conventional willingness-to-pay thresholds ($100,000 per quality-adjusted life-year) only when priced at $7,500 to $9,400 annually, well below the current list price but within range of savings-card and compounded pricing [10].

South Carolina-Specific Pharmacy and Regulatory Notes

South Carolina's Board of Pharmacy regulates compounding pharmacies under SC Code § 40-43-86. The state does not impose additional restrictions on 503A compounding beyond federal requirements under the Drug Quality and Security Act (DQSA). This means any pharmacy with a valid South Carolina compounding permit and USP 797 compliance can prepare tirzepatide for individual patients with valid prescriptions.

The SC Department of Insurance does not mandate commercial coverage of anti-obesity medications. Coverage decisions rest with individual carriers and self-funded employer plans. South Carolina's State Health Plan for state employees covered Wegovy (semaglutide 2.4 mg) on a limited basis starting in plan year 2025, but Zepbound has not yet been added to the State Health Plan formulary.

For patients using telehealth, South Carolina requires prescribers to hold an active SC medical license or be registered through an interstate compact (IMLC). Verify that your telehealth prescriber meets this requirement before beginning treatment.

The South Carolina obesity rate stood at 36.4% in the most recent CDC BRFSS data, ranking the state 14th nationally for adult obesity prevalence [3]. An estimated 1.3 million South Carolina adults meet BMI criteria for Zepbound eligibility.